Re: [新聞] 高端疫苗可對抗變異株 數據登CID期刊公

塔綠班不敢面對的真相就是，高端自己在文章提到自己沒有保護力資料，只能說自己中和抗體很多（跟之前大家就已經知道的故事差在哪？）

然後，高端自己也提到，自己是在中和抗體最高的時間點取血清（跟愛刷存在感的某前版主一樣），但血清之後變低還有沒有保護效果不知道，因為牽扯到t細胞的免疫反應，無法得知。（也就跟大家說的一樣，沒有保護力資料，根本是假的）

不過塔綠班還是高潮的很爽啦！嘻嘻

A limitation of our study is that the sera were taken 4 weeks after the second shot of MVC-COV1901 when immunity has peaked and only just started to wane. Therefore, we could not evaluate the impact of waning immunity on the neutralizing capacity against the variants. The study cannot evaluate the role of T-cell responses elicited by the vaccine as it was reported that the T-cell responses to immunization may confer heterotypic coverage and are less affected by VoCs [31].

COVID-19 vaccines in phase 3 clinical trials in South Africa when the Beta variant became predominant showed considerably high protection against severe clinical endpoints, while overall efficacy is lower than at sites outside of South Africa [32].

Since there are no correlates of protection being published for emerging variants, it warrants further study on how the reduced neutralizing titers will translate to clinical endpoints. We are currently conducting a randomized, double-blind, placebo-controlled phase 2 study for safety and immunogenicity of MVC-COV1901 with >3800 subjects (NCT04695652). The samples from the phase 2 trialwould allow us to further investigate the effects of variants on neutralizingtiters by using a larger set of samples and newer variants.

--

崩潰了啊？嘻嘻

T細胞沒法測，所以人家用三期來直接證明保護力，不像高端到現在端不出三期呀